104 related articles for article (PubMed ID: 38713018)
1. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis.
Vincelette ND; Yu X; Kuykendall AT; Moon J; Su S; Cheng CH; Sammut R; Razabdouski TN; Nguyen HV; Eksioglu EA; Chan O; Al Ali N; Patel PC; Lee DH; Nakanishi S; Ferreira RB; Hyjek E; Mo Q; Cory S; Lawrence HR; Zhang L; Murphy DJ; Komrokji RS; Lee D; Kaufmann SH; Cleveland JL; Yun S
Blood Cancer Discov; 2024 May; ():. PubMed ID: 38713018
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
[TBL] [Abstract][Full Text] [Related]
3. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
5. Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Varricchio L; Hoffman R
Front Oncol; 2022; 12():906698. PubMed ID: 35646681
[TBL] [Abstract][Full Text] [Related]
6. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
[TBL] [Abstract][Full Text] [Related]
7. Circulating CD133+/–CD34– Have Increased c-
Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
[TBL] [Abstract][Full Text] [Related]
8. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38548563
[TBL] [Abstract][Full Text] [Related]
9. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
10. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
Kapor S; Momčilović S; Kapor S; Mojsilović S; Radojković M; Apostolović M; Filipović B; Gotić M; Čokić V; Santibanez JF
Adv Exp Med Biol; 2023; 1408():273-290. PubMed ID: 37093433
[TBL] [Abstract][Full Text] [Related]
11. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
12. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
13. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
14. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
Calabresi L; Balliu M; Bartalucci N
Methods Cell Biol; 2022; 171():81-109. PubMed ID: 35953207
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of myelofibrosis.
Komrokji RS; Verstovsek S; Padron E; List AF
Cancer Control; 2012 Oct; 19(4 Suppl):4-15. PubMed ID: 23042420
[TBL] [Abstract][Full Text] [Related]
16. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in therapies for primary myelofibrosis.
Vainchenker W; Yahmi N; Havelange V; Marty C; Plo I; Constantinescu SN
Fac Rev; 2023; 12():23. PubMed ID: 37771602
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
19. The role of JAK2 inhibitors in MPNs 7 years after approval.
Passamonti F; Maffioli M
Blood; 2018 May; 131(22):2426-2435. PubMed ID: 29650801
[TBL] [Abstract][Full Text] [Related]
20. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]